Your browser doesn't support javascript.
loading
Dynamics of liver stiffness measurement and clinical course of primary biliary cholangitis.
Lam, Laurent; Soret, Pierre-Antoine; Lemoinne, Sara; Hansen, Bettina; Hirschfield, Gideon; Gulamhusein, Aliya; Montano-Loza, Aldo J; Lytvyak, Ellina; Parés, Albert; Olivas, Ignasi; Londono, Maria-Carlota; Rodríguez-Tajes, Sergio; Eaton, John E; Osman, Karim T; Schramm, Christoph; Sebode, Marcial; Lohse, Ansgar W; Dalekos, George; Gatselis, Nikolaos; Nevens, Frederik; Cazzagon, Nora; Zago, Alessandra; Russo, Francesco Paolo; Floreani, Annarosa; Abbas, Nadir; Trivedi, Palak; Thorburn, Douglas; Saffioti, Francesca; Barkai, Laszlo; Roccarina, Davide; Calvaruso, Vicenza; Fichera, Anna; Delamarre, Adèle; Sobenko, Natalia; Villamil, Alejandra Maria; Medina-Morales, Esli; Bonder, Alan; Patwardhan, Vilas; Rigamonti, Cristina; Carbone, Marco; Invernizzi, Pietro; Cristoferi, Laura; van der Meer, Adriaan; de Veer, Rozanne; Zigmond, Ehud; Yehezkel, Eyal; Kremer, Andreas E; Deibel, Ansgar; Bruns, Tony; Große, Karsten.
Afiliação
  • Lam L; Sorbonne University, Inserm, Pierre Louis Institute of Epidemiology and Public Health, Paris; Public Health Unit, Saint-Antoine Hospital, Assistance Publique - Hôpitaux de Paris, European Reference Network on Hepatological Diseases (ERN Rare-Liver), France.
  • Soret PA; Reference Center for Inflammatory Biliary Diseases and Autoimmune Hepatitis, European Reference Network on Hepatological Diseases (ERN Rare-Liver), Saint-Antoine Hospital, Assistance Publique - Hôpitaux de Paris; Inserm UMR_S938, Saint-Antoine Research Center, Sorbonne University, Paris, France.
  • Lemoinne S; Reference Center for Inflammatory Biliary Diseases and Autoimmune Hepatitis, European Reference Network on Hepatological Diseases (ERN Rare-Liver), Saint-Antoine Hospital, Assistance Publique - Hôpitaux de Paris; Inserm UMR_S938, Saint-Antoine Research Center, Sorbonne University, Paris, France.
  • Hansen B; Toronto Centre for Liver Disease, University Health Network, University of Toronto, Toronto, Canada; Department of Epidemiology & Biostatistics, Erasmus MC, Rotterdam, the Netherlands.
  • Hirschfield G; Toronto Centre for Liver Disease, University Health Network, University of Toronto, Toronto, Canada.
  • Gulamhusein A; Toronto Centre for Liver Disease, University Health Network, University of Toronto, Toronto, Canada.
  • Montano-Loza AJ; Division of Gastroenterology and Liver Unit, University of Alberta, Edmonton, Canada.
  • Lytvyak E; Division of Preventive Medicine, University of Alberta, Edmonton, Alberta, Canada.
  • Parés A; Liver Unit, Hospital Clínic Barcelona, Institut de Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (CIBEREHD), University of Barcelona, University of Barcelona, European Reference Network on Hepatological Diseases
  • Olivas I; Liver Unit, Hospital Clínic Barcelona, Institut de Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (CIBEREHD), University of Barcelona, University of Barcelona, European Reference Network on Hepatological Diseases
  • Londono MC; Liver Unit, Hospital Clínic Barcelona, Institut de Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (CIBEREHD), University of Barcelona, University of Barcelona, European Reference Network on Hepatological Diseases
  • Rodríguez-Tajes S; Liver Unit, Hospital Clínic Barcelona, Institut de Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (CIBEREHD), University of Barcelona, University of Barcelona, European Reference Network on Hepatological Diseases
  • Eaton JE; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, USA.
  • Osman KT; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, USA.
  • Schramm C; Department of Medicine I and Martin Zeitz Center for Rare Diseases, European Reference Network on Hepatological Diseases (ERN Rare-Liver), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Sebode M; Department of Medicine I and Martin Zeitz Center for Rare Diseases, European Reference Network on Hepatological Diseases (ERN Rare-Liver), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Lohse AW; Department of Medicine I and Martin Zeitz Center for Rare Diseases, European Reference Network on Hepatological Diseases (ERN Rare-Liver), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Dalekos G; Department of Medicine and Research Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, European Reference Network on Hepatological Diseases (ERN Rare-Liver), General University Hospital, Larissa, Greece.
  • Gatselis N; Department of Medicine and Research Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, European Reference Network on Hepatological Diseases (ERN Rare-Liver), General University Hospital, Larissa, Greece.
  • Nevens F; Division of Hepatology and Liver Transplantation, European Reference Network on Hepatological Diseases (ERN Rare-Liver), University Hospitals KU, Leuven, Belgium.
  • Cazzagon N; Department of Surgery, Oncology and Gastroenterology, European Reference Network on Hepatological Diseases (ERN Rare-Liver), University of Padova, Padova, Italy.
  • Zago A; Department of Surgery, Oncology and Gastroenterology, European Reference Network on Hepatological Diseases (ERN Rare-Liver), University of Padova, Padova, Italy.
  • Russo FP; Department of Surgery, Oncology and Gastroenterology, European Reference Network on Hepatological Diseases (ERN Rare-Liver), University of Padova, Padova, Italy.
  • Floreani A; Department of Surgery, Oncology and Gastroenterology, European Reference Network on Hepatological Diseases (ERN Rare-Liver), University of Padova, Padova, Italy.
  • Abbas N; Liver Unit, University Hospitals Birmingham National Health Service Foundation Trust Queen Elizabeth, Birmingham, United Kingdom.
  • Trivedi P; National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre (BRC), Institute of Immunology and Immunotherapy, Centre for Liver and Gastrointestinal Research, University of Birmingham, Birmingham B15 2TT, United Kingdom.
  • Thorburn D; University College London Institute for Liver and Digestive Health, Royal Free Hospital, London, United Kingdom.
  • Saffioti F; University College London Institute for Liver and Digestive Health, Royal Free Hospital, London, United Kingdom.
  • Barkai L; University College London Institute for Liver and Digestive Health, Royal Free Hospital, London, United Kingdom.
  • Roccarina D; University College London Institute for Liver and Digestive Health, Royal Free Hospital, London, United Kingdom.
  • Calvaruso V; Section of Gastroenterology and Hepatology, PROMISE, University of Palermo, Palermo, Italy.
  • Fichera A; Section of Gastroenterology and Hepatology, PROMISE, University of Palermo, Palermo, Italy.
  • Delamarre A; Department of Hepatology, University Hospitals of Bordeaux, Pessac, France.
  • Sobenko N; Department of Hepatology & Liver Transplantation, Italian Hospital of Buenos Aires, Argentina.
  • Villamil AM; Department of Hepatology & Liver Transplantation, Italian Hospital of Buenos Aires, Argentina.
  • Medina-Morales E; Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, USA.
  • Bonder A; Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, USA.
  • Patwardhan V; Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, USA.
  • Rigamonti C; Department of Translational Medicine, Università del Piemonte Orientale and Division of Internal Medicine, AOU Maggiore della Carità, Novara, Italy.
  • Carbone M; Division of Gastroenterology, Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
  • Invernizzi P; Division of Gastroenterology, Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
  • Cristoferi L; Division of Gastroenterology, Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
  • van der Meer A; Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • de Veer R; Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Zigmond E; The Research Center for Digestive Tract and Liver Diseases, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Yehezkel E; The Research Center for Digestive Tract and Liver Diseases, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Kremer AE; Department of Gastroenterology and Hepatology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
  • Deibel A; Department of Gastroenterology and Hepatology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
  • Bruns T; Department of Medicine III, University Hospital RWTH Aachen, European Reference Network on Hepatological Diseases (ERN Rare-Liver), Aachen, Germany.
  • Große K; Department of Medicine III, University Hospital RWTH Aachen, European Reference Network on Hepatological Diseases (ERN Rare-Liver), Aachen, Germany.
Article em En | MEDLINE | ID: mdl-39019421
ABSTRACT
BACKGROUND &

AIMS:

In primary biliary cholangitis (PBC), static liver stiffness measurement (LSM) has proven prognostic value. However, the added prognostic value of LSM time course in this disease remains uncertain.

METHODS:

We conducted an international retrospective cohort study among PBC patients treated with ursodeoxycholic acid (UDCA) and followed by vibration-controlled transient elastography (VCTE) between 2003 and 2022. Using joint modeling, the association of LSM trajectory and the incidence of serious clinical events (SCE), defined as cirrhosis complications, liver transplantation (LT) or death, was quantified using the hazard ratio (HR) and its confidence interval (CI).

RESULTS:

A total of 6,362 LSMs were performed in 3,078 patients (2,007 on UDCA alone; 13% with cirrhosis), in whom 316 SCE occurred over 14,445 person-years (median follow-up, 4.2 years; incidence rate, 21.9 per 1,000 person-years). LSM progressed in 59% of patients (mean 0.39 kPa/year). After adjusting for prognostic factors at baseline, including LSM, any relative change in LSM was associated with a significant variation in SCE risk (p<0.001). For example, the adjusted HRs (95% CI) associated with a 20% annual variation in LSM were 2.13 (1.89 - 2.45) for the increase and 0.40 (0.33 - 0.46) for the decrease. The association between LSM trajectory and SCE risk persisted regardless of treatment response or duration, when patients with cirrhosis were excluded, and when only death or LT was considered.

CONCLUSIONS:

Tracking longitudinal changes in LSM using VCTE provides valuable insights into PBC prognosis, offering a robust predictive measure for the risk of SCE. LSM could be used as a clinically relevant surrogate endpoint in PBC clinical trials.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Clin Gastroenterol Hepatol Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Clin Gastroenterol Hepatol Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: França
...